DRG Epidemiology’s coverage of insomnia comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China, India, Mexico, Russia, South Korea, and Turkey). We report the prevalence of insomnia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered.

DRG Epidemiology’s insomnia forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of insomnia over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following insomnia subpopulations:

  • Total DSM-IV prevalent cases by anxiety and mood disorder comorbidity status.
  • Total DSM-V prevalent cases by anxiety and mood disorder comorbidity status.
  • Total DSM-IV prevalent cases by obstructive sleep apnea comorbidity status.
  • Total DSM-V prevalent cases by obstructive sleep apnea comorbidity status.

Note: Coverage may vary by country.

Table of contents

  • Emerging Markets
    • Introduction
      • Key Findings
      • Total Prevalence Estimates of Insomnia per 100 People Aged 15 or Older in 2019 and 2029
      • Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Insomnia over the Next Ten Years
    • Epidemiology Data
    • Methods
      • Total DSM-V Prevalent Cases
      • Total DSM-IV Prevalent Cases
      • Comorbidity Cases
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Atul Sharma, MPH

Atul Sharma started working in Decision Resources Group as an intern in early 2016 and currently works as an associate epidemiologist. He performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. He produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. He holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from MN DAV Dental College & Hospital.

Related Reports

Insomnia | Access & Reimbursement | Detailed, Expanded Analysis (US)

Insomnia is a highly prevalent condition with obvious indirect economic costs, but payers may not be fully aware of the healthcare cost savings that could result from ensuring patient access to e...

View Details